V. Cottin (Lyon, France), S. Tomassetti (Forli, Italy)
Late Breaking Abstract - Prevalence and clinical significance of antinuclear antibody (ANA) in IPF: analysis from ESTAIR study
P. Wung (Bridgewater, United States of America), G. Raghu (Seattle, United States of America), B. Crestani (Paris, France), L. Richeldi (Rome, Italy), C. Esperet (Paris, France), C. Soubrane (Paris, France)
|    |
Four metre gait speed (4MGS) predicts mortality and hospitalisation in IPF
C. Nolan (London, United Kingdom), M. Maddocks (London, United Kingdom), T. Maher (London, United Kingdom), S. Jones (London, United Kingdom), S. Patel (London, United Kingdom), R. Barker (London, United Kingdom), P. George (London, United Kingdom), P. Cullinan (London, United Kingdom), W. Man (London, United Kingdom)
| |
A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey
M. Kreuter (Heidelberg, Germany), M. Polke** (Heidelberg, Germany), S. Walsh (London, United Kingdom), H. Collard (San Francisco, United States of America), N. Chaudhuri (Manchester, United Kingdom), S. Avdeev (Moscow, Russian Federation), J. Behr (Gauting, Germany), G. Calligero (Cape Town, South Africa), T. Corte (Sydney, Australia), K. Flaherty (Ann Arbor, United States of America), M. Funke (Bern, Switzerland), M. Kolb (Hamilton, Canada), Y. Kondoh (Aichi, Japan), T. M. Maher (London, United Kingdom), M. Molina Molina (Barcelona, Spain), A. Morais (Porto, Portugal), K. Moor (Rotterdam, Netherlands), J. Morisset (Quebec, Canada), C. Pereira (São Paulo, Brazil), S. Quadrelli (Buenos Aires, Argentina), M. Selman (México City, Mexico), A. Tzouvelekis (Athens, Greece), C. Vancheri (Catania, Italy), V. Vicens-Zygmunt (Barcelona, Spain), J. Waelscher (Heidelberg, Germany), W. Wuyts (Leuven, Belgium), M. Wijsenbeek** (Rotterdam, Netherlands), V. Cottin** (Lyon, France), E. Bendstrup** (Aarhus, Denmark)
| |
Associations of interstitial lung abnormalities with physical function measures
G. Axelsson (Reykjavik, Iceland), R. Putman (Boston, Mass., United States of America), E. Miller (Boston, Mass., United States of America), T. Araki (Boston, Mass., United States of America), S. Sigurdsson (Kopavogur, Iceland), E. Gudmundsson (Kopavogur, Iceland), G. Eiriksdottir (Kopavogur, Iceland), K. Siggeirsdottir (Kopavogur, Iceland), T. Aspelund (Kopavogur, Iceland), L. Launer (Bethesda, United States of America), T. Harris (Bethesda, United States of America), H. Hatabu (Boston, Mass., United States of America), V. Gudnason (Kopavogur, Iceland), G. Hunninghake (Boston, Mass., United States of America), G. Gudmundsson (Reykjavik, Iceland)
| |
INTERSTITIAL LUNG DISEASE IN A LUNG CANCER SCREENING PROGRAM: PREVALENCE AND ASSOCIATION WITH CANCER.
A. Campo Ezquibela (Pamplona, Spain), A. Merino Hernandez (Pamplona, Spain), J. Gonzalez Gutierrez (Pamplona, Spain), M. Marin Oto (Pamplona, Spain), A. Alcaide Ocana (Pamplona, Spain), J. De Torres Tajes (Pamplona, Spain), J. Zulueta Frances (Pamplona, Spain)
| |
Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the Adipose Derived Stromal Cells-Stromal Vascular Fraction in Idiopathic Pulmonary Fibrosis
P. Ntolios (Alexandroupolis, Greece), E. Manoloudi (Alexandroupolis, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), P. Steiropoulos (Alexandroupolis, Greece), S. Anevlavis (Alexandroupolis, Greece), D. Bouros (Athens, Greece), M. Froudarakis (Alexandroupolis, Greece)
| |
Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial
M. Kolb (Hamilton, Ontario, Canada), A. Wells (London, United Kingdom), J. Behr (Munich, Germany), L. Richeldi (Rome, Italy), B. Schinzel (Heidelberg, Germany), M. Quaresma (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), G. Raghu (Seattle, Washington, United States of America), F. Martinez (New York, New York, United States of America)
| |
Contribution of mutations in genes of the surfactant system to idiopathic interstitial pneumonia (IIP)
N. Nathan (Paris, France), M. Legendre (Paris, France), E. Filhol-Blin (Paris, France), R. Borie (Paris, France), D. Bouvry (Bobigny, France), M. Afanetti (Nice, France), K. Ahmad (Lyon, France), J. Albuisson (Paris, France), N. Allou (Saint Denis de La Réunion, France), C. Bailly (Nice, France), K. Borensztajn (Paris, France), A. Butt (Paris, France), B. Copin (Paris, France), A. Coulomb L'Hermine (Paris, France), B. Crestani (Paris, France), J. Dalphin (Besancon, France), M. Dalphin (Besancon, France), F. Dastot Le Moal (Paris, France), C. Delacourt (Paris, France), B. Delaisi (Paris, France), A. Deschildre (Lille, France), P. De Vuyst (Brussels, Belgium), B. Diot (Tours, France), C. Dromer (Bordeaux, France), J. Dubus (Marseille, France), P. Duquesnoy (Paris, France), L. Giovannini-Chami (Nice, France), V. Giraud (Bouogne Billancourt, France), C. Gomez (Marseille, France), A. Gondouin (Besançon, France), L. Gouya (Colombes, France), A. Hadchouel (Paris, France), S. Hirschi (Strasbourg, France), V. Houdouin (Paris, France), D. Israel Biet (Paris, France), C. Kannengiesser (Paris, France), C. Lefevre (Paris, France), E. Manali (Athens, Greece), S. Marchand-Adam (Tours, France), C. Marguet (Rouen, France), J. Naccache (Paris, France), V. Nau (Paris, France), H. Nunes (Bobigny, France), O. O'Connell (Dublin, Ireland), K. O'Reilly (Dublin, Ireland), S. Papiris (Athens, Greece), C. Picard (Suresnes, France), G. Prevot (Toulouse, France), P. Reix (Lyon, France), M. Reynaud-Gaubert (Marseille, France), E. Rivaud (Suresnes, France), E. Schaefer (Strasbourg, France), A. Tatopoulos (Nancy, France), J. Traclet (Lyon, France), F. Troussier (Angers, France), D. Valeyre (Bobigny, France), V. Cottin (Lyon, France), A. Clement (Paris, France), S. Amselem (Paris, France)
| |